Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.
The company’s consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.
The scrip rose 0.36% to Rs 1,197.40 on the BSE.
Click here to visit SEBI Scores